...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Treatment of Osteoarthrosis with Piroxicam in General Practice: Long-Term Follow-Up in a Multicentre Study
【24h】

Treatment of Osteoarthrosis with Piroxicam in General Practice: Long-Term Follow-Up in a Multicentre Study

机译：一般实践中使用吡罗昔康治疗骨关节炎：一项多中心研究的长期随访

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Thirty-eight investigators in Belgium, Finland, Germany, Italy and The Netherlands participated in a long-term follow-up of 154 patients who had shown adequate response without toleration problems in a short-term multicentre trial in osteoarthrosis. Patients were from 37 to 85 years of age (mean 63) and 68% were female. They received piroxicam from 92 to 344 days (mean 182). The starting dose of 20 mg once daily was maintained throughout for 69% of patients; for 12% the final dose was 30 mg, for 16% it was 10 mg, and for 3% it was 40 mg. Forty-seven per cent of patients reported they were taking concurrent anti-inflammatory/analgesic medication at baseline but by the end of therapy only 18% were. Most patients had moderate or severe involvement in one or more of the knee, hip, spine, shoulder, and finger joints. By the final visit, between 84% and 94% showed marked or moderate improvement in the physician's assessment of joint tenderness and limitation of motion. These results were in good agreement with patient self assessment: 83% to 90% reported marked or moderate improvement in ability to move and use joints and in their general overall feeling (‘quality of life’ measurement). Furthermore, steady improvement was observed throughout therapy in patient self-assessment of pain and stiffness relative to baseline. The 50% to 60% pain reduction recorded over the short-term (6 to 12 weeks) reached 70% at the end of therapy. The figures for stiffness were 50% to 55% short-term and 61% long-term. Onset of morning pain which occurred on the average within 1 hour of waking at baseline had risen to 8.4 hours (740% increase) by the end of therapy. The drug was well tolerated with sixteen patients (10%) reporting side-effects attributed to piroxicam. Nearly all were mild or moderate and occurred without disruption of therapy during the first 1 or 2 months of treatment. Most adverse reactions were upper gastro-intestinal but there were no reports of ulceration. One patient, with gastro-intestinal pain after 99 days on drug, was discontinued. In their global evaluation, physicians judged the efficacy of piroxicam as marked in 71%, moderate in 24%, slight in 4%, and not effective in 1% of patients. Toleration was considered excellent in 83%, good in 14 %, fair in 2%, and poor in only 1%. Compared to prior therapy, piroxicam was rated by the investigators as better in 90% of the 114 assessable cases. The results suggest that patients with osteoarthrosis who respond well to piroxicam during a short course of treatment are likely to continue their good response and possibly obtain increased relief of symptoms during longer treatment periods.
机译：比利时，芬兰，德国，意大利和荷兰的38名研究者参加了对154例长期随访患者的随访，这些患者在骨关节炎的多中心短期试验中显示出足够的反应且没有耐受性问题。患者年龄在37至85岁之间（平均63岁），其中68％为女性。他们在92到344天（平均182天）接受吡罗昔康治疗。 69％的患者每天维持一次20 mg的起始剂量。对于12％，最终剂量为30 mg，对于16％，最终剂量为10 mg，对于3％，最终剂量为40 mg。 47％的患者报告他们在基线时正在同时服用抗炎/镇痛药，但到治疗结束时只有18％。大多数患者的膝盖，髋部，脊柱，肩部和手指关节中的一个或多个受累中度或重度。最终访视时，有84％至94％的患者在医师评估关节压痛和运动受限方面显示出明显或中度改善。这些结果与患者的自我评估非常吻合：83％至90％的患者报告说，其活动和使用关节的能力以及总体感觉（“生活质量”测量）有明显或中等程度的改善。此外，在整个治疗过程中，患者相对于基线的疼痛和僵硬自我评估均观察到稳定的改善。短期（6至12周）记录的疼痛减轻50％至60％在治疗结束时达到70％。刚度的数字是短期的50％至55％，长期的61％。到治疗结束时，平均在基线清醒后1小时内发生的早晨疼痛发作已上升至8.4小时（增加740％）。该药物耐受良好，有16位患者（10％）报告了吡罗昔康引起的副作用。几乎所有患者均为轻度或中度，并且在治疗的前1或2个月内没有中断治疗。大多数不良反应是上消化道，但没有溃疡的报道。停止使用药物99天后出现胃肠道疼痛的一名患者。在他们的总体评估中，医生们判断吡罗昔康的疗效显着为71％，中度为24％，轻度为4％，而对1％的患者无效。宽容度被认为是83％优秀，14％良好，2％中等，仅1％较差。与之前的治疗相比，研究人员将吡罗昔康评估为114例可评估病例中的90％较好。结果表明，在短期疗程中对吡罗昔康反应良好的骨关节炎患者很可能会继续保持良好的反应，并且在较长的治疗期间可能会减轻症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号